Precision BioSciences, Inc. (DTIL) Stock Forecast
Data as of Aug 8, 2026Healthcare · Current price $7.43 (+0.13%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
DTIL vs Sector & Market
| Metric | DTIL | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.25 | 2.42 |
| Analyst Count | 2 | 8 | 18 |
| Target Upside | +162.4% | +16286.2% | +14.7% |
| P/E Ratio | -1.95 | 3.59 | 36.06 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $13M | $13M | $13M | 3 |
| 2027-12-31 | $13M | $13M | $13M | 3 |
| 2028-12-31 | $14M | $14M | $14M | 4 |
| 2029-12-31 | $21M | $21M | $21M | 3 |
| 2030-12-31 | $108M | $108M | $108M | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-2.94 | $-2.94 | $-2.94 | 2 |
| 2027-12-31 | $-2.75 | $-2.75 | $-2.75 | 2 |
| 2028-12-31 | $-3.30 | $-2.70 | $-1.96 | 4 |
| 2029-12-31 | $-2.70 | $-2.70 | $-2.70 | 2 |
| 2030-12-31 | $-0.97 | $-0.97 | $-0.97 | 2 |
Frequently Asked Questions
What is the analyst consensus for DTIL?
The consensus among 2 analysts covering Precision BioSciences, Inc. (DTIL) is Buy with an average price target of $19.00.
What is the highest price target for DTIL?
The highest analyst price target for DTIL is $19.00.
What is the lowest price target for DTIL?
The lowest analyst price target for DTIL is $19.00.
How many analysts cover DTIL?
2 analysts have issued ratings for Precision BioSciences, Inc. in the past 12 months.
Is DTIL a buy or sell right now?
Based on 2 analyst ratings, DTIL has a consensus rating of Buy (2.00/5) with a +162.4% upside to the consensus target of $19.00.
What are the earnings estimates for DTIL?
Analysts estimate DTIL will report EPS of $-2.94 for the period ending 2026-12-31, with revenue estimated at $13M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.